Pfizer Says Its Booster Provides Protection Against Omicron Variant

Pfizer Says Its
Booster Provides , Protection Against Omicron Variant.
Pfizer Says Its
Booster Provides , Protection Against Omicron Variant.
NBC News reports officials with
Pfizer-BioNTech say a booster dose of the companies' coronavirus vaccine supplies ample protection against the new Omicron variant.
NBC News reports officials with
Pfizer-BioNTech say a booster dose of the companies' coronavirus vaccine supplies ample protection against the new Omicron variant.
Research shows their booster shot offers a similar degree of protection as two regular doses of their vaccine does against the original COVID-19 strain.
Three doses against Omicron are almost equivalent to the two doses effectiveness we had against the... original variant. , Albert Bourla, CEO Pfizer, via NBC News.
Lab tests suggest two doses of the Pfizer-BioNTech vaccine experience a 25-fold drop in efficacy when matched against the Omicron strain.
An independent study showed the Pfizer
vaccine's regular dose experienced a forty-fold reduction in neutralizing antibodies. .
An independent study showed the Pfizer
vaccine's regular dose experienced a forty-fold reduction in neutralizing antibodies. .
Officials say these
results are preliminary.
More data will be necessary.
Initially found in South Africa, the
heavily-mutated Omicron variant is
quickly spreading around the globe.
Initially found in South Africa, the
heavily-mutated Omicron variant is
quickly spreading around the globe.
Pfizer says it has begun work on an
Omicron-specific vaccine. According to officials it could be ready in around 100 days.
If we need a new vaccine, those
tests are telling me we will be able to have a very good
one if we need one. , Albert Bourla, CEO Pfizer, via NBC News.
The current booster will maintain protection, but if we need one,
we will make one and
we will have it by March. , Albert Bourla, CEO Pfizer, via NBC News .
The current booster will maintain protection, but if we need one,
we will make one and
we will have it by March. , Albert Bourla, CEO Pfizer, via NBC News